Synonyms that are in the dictionary are marked in green. Synonyms that are not in the dictionary are marked in red.
Antonyms that are in the dictionary are marked in green. Antonyms that are not in the dictionary are marked in red.
Charles River Laboratories International, Inc. has a twelve month low of $181.36 and a twelve month high of $349.84.
Charles River Laboratories International stock opened at $249.82 on Friday.
Commonwealth Equity Services LLC’s holdings in Charles River Laboratories International were worth $4,278,000 at the end of the most recent reporting period.
Deutsche Bank Aktiengesellschaft cut their price objective on Charles River Laboratories International from $260.00 to $250.00 in a research report on Friday, May 12th.
Finally, Covestor Ltd grew its position in Charles River Laboratories International by 100.0% in the 1st quarter.
Fortunately for investors in Charles River Laboratories International), the stock is not so lofty as to limit potential by any meaningful degree.
Huntington National Bank boosted its position in shares of Charles River Laboratories International by 53.7% during the 3rd quarter.
In other Charles River Laboratories International news, EVP Shannon M. Parisotto sold 2,279 shares of Charles River Laboratories International stock in a transaction dated Tuesday, November 15th.
In other Charles River Laboratories International news, EVP Shannon M. Parisotto sold 2,279 shares of Charles River Laboratories International stock in a transaction dated Tuesday, November 15th.
In other Charles River Laboratories International news, EVP Shannon M. Parisotto sold 4,558 shares of the company’s stock in a transaction dated Thursday, February 16th.
Kentucky Retirement Systems Insurance Trust Fund bought a new stake in shares of Charles River Laboratories International, Inc. () in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission.
Key players profiled include AGC Biologics, Charles River Laboratories, Catalent, Danaher (Cytiva), Lonza, Merck KGaA, and others, contributing to the market's evolution.
On average, analysts forecast that Charles River Laboratories International, Inc. will post 10.31 earnings per share for the current fiscal year.
Panagora Asset Management Inc. increased its position in shares of Charles River Laboratories International by 236.5% during the first quarter.
Wells Fargo & Company lowered their target price on Charles River Laboratories International from $280.00 to $275.00 and set an “overweight” rating for the company in a research report on Friday, September 22nd.